Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

18.77 +0.13 (+0.70%)
Streaming Delayed Price Updated: 9:41 AM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Why Is Summit Therapeutics Stock Trading Higher On Monday?
Summit Therapeutics highlights China approval of Akeso's ivonescimab for NSCLC, with enrollment ongoing for Phase 3 HARMONi-7 trial. 
Via Benzinga
Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Benzinga Bulls And Bears: Netflix, Novavax, Intel — And The Market Begins To Bounce Back
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today
Via The Motley Fool
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
What's Going On With Summit Therapeutics Stock On Friday?
Summit Therapeutics' partner Akeso received FDA approval for penpulimab-kcqx in NPC, while ivonescimab showed strong data in lung cancer trials. 
Via Benzinga
Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China
From Summit Therapeutics Inc.
Via Business Wire
Top stock movements in today's session.
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
Summit Therapeutics Stock Slumps After Partner Akeso Gets FDA Nod For Cancer Drug: Retail’s Optimistic
The company’s lead candidate, ivonescimab, aimed at treating certain cancers, was discovered by Akeso and is currently in multiple late-stage clinical trials. 
Via Stocktwits
Topics Artificial Intelligence
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics Retail Traders Stoked As Stock Surges On Promising Cancer Drug Trial
The study was conducted across multiple centers in China, comparing ivonescimab plus chemotherapy against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy. 
Via Stocktwits
Why Summit Therapeutics Rocketed Double-Digits Today
Via The Motley Fool
Topics World Trade
Why Is Summit Therapeutics Stock Soaring On Wednesday?
Summit and Akeso report Phase 3 success as ivonescimab shows PFS gains in NSCLC trial, with new studies and collaborations underway. 
Via Benzinga
BioNTech Surges On Summit's Coattails. But Can They Take On Merck?
BioNTech is on the rise after Summit Therapeutics unveiled promising results for its PD-1- and VEGF-blocking drug. 
Via Investor's Business Daily
Amphenol Posts Better-Than-Expected Results, Joins SAP, Tesla, Pegasystems And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China
From Summit Therapeutics Inc.
Via Business Wire
This Company's Co-CEOs Just Bought More Shares. Should You?
Via The Motley Fool
In The Holiday Shortened Easter Week, These Large-Cap Stock Were Top Performers (Apr 14-Apr 18): Are These In Your Portfolio?
Top performers last week: ServiceTitan, Summit Therapeutics, YPF, Eli Lilly, MicroStrategy, America Movil, Ericsson, Insmed, Diamondback, Neurocrine Biosciences. 
Via Benzinga
Top 3 Health Care Stocks You May Want To Dump This Quarter
 
Via Benzinga
Top 3 Biotech Stocks That Got Retail Street Buzzing Last Week: SMMT, PTN, RXRX
Positive expectations from key clinical trials, delisting fears and some regulatory changes triggered a flurry of discussions on Stocktwits for these tickers for the week ended April 11, 2025. 
Via Stocktwits
Topics Animal Testing
Gold Related Large-Cap Stocks Outperformed In One Of The Most Volatile Weeks (Apr 7-Apr 11): Are These In Your Portfolio?
Last week's top performers: SMMT, HMY, AU, CVNA, HOOD, NEM, AVGO, GFI, KGC, CEG. Are they in your portfolio? #stockmarket #investing 
Via Benzinga
3 Magnificent Stocks That Could Double or More by 2030
Via The Motley Fool
Why Summit Therapeutics Rallied Double Digits Today on Another Down day for the Markets
Via The Motley Fool
Topics ETFs
PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
2 Stocks That Have More Than Doubled in the Past Year to Buy and Hold for a Decade
Via The Motley Fool
Topics Government
3 Growth Stocks That Have Dwarfed Nvidia's Returns Over the Past 12 Months
Via The Motley Fool
Topics Artificial Intelligence Economy World Trade
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today
Via The Motley Fool
Topics Government World Trade
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.
Via The Motley Fool
Topics Intellectual Property Retirement
Why Summit Therapeutics Stock Slipped Today
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.